The Medicines Co. Orbactiv approved by FDA The Medicines Company announced that the FDA has approved Orbactiv for injection for the treatment of adults with acute bacterial skin and skin structure infections, or ABSSSI, caused by susceptible designated Gram-positive bacteria including methicillin-resistant Staphylococcus aureus. Orbactiv is the first and only antibiotic approved by FDA to treat ABSSSIs with a single, once-only administration. Once fully infused over three hours, the Orbactiv treatment regimen is complete for patients with skin infections caused by susceptible Gram-positive pathogens.
Cowen to hold a conference 35th Annual Health Care Conference is being held in Boston on March 2-4 with webcasted company presentations to begin on March 3 at 8 am; not all company presentations may be webcasted. Webcast Link